Deloitte, a global leader in consulting and advisory services, has just expanded its innovative Quartz AI™ suite with the addition of Atlas AI™, specifically designed to revolutionize the drug discovery process. Announced on January 8, 2024, Atlas AI™ is the first offering in the life sciences and health care sector under the Quartz umbrella, designed to significantly accelerate research and the introduction of new drugs to the market.
Atlas AI™ is a first-of-its-kind Generative AI solution that synergizes NVIDIA BioNeMo cloud APIs with Deloitte’s extensive industry experience and a team of skilled AI professionals. This pioneering approach aims to reimagine the drug discovery process by integrating Generative AI models, knowledge representation, reasoning, and custom Large La
Deloitte and NVIDIA Collaborate to Transform Drug Discovery with Atlas AI™
- By 재은
- Published on
Deloitte expands its Quartz AI™ suite with the launch of Atlas AI™, a groundbreaking Generative AI solution for drug discovery, combining NVIDIA BioNeMo cloud APIs with Deloitte’s expertise to revolutionize and accelerate the drug development process.
